FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements
Share
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with long-standing customers; and (d) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.
The truth about this fraud was revealed over a series of disclosures culminating on February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts. West attributed the disappointing guidance in part to contract manufacturing headwinds, including the loss of two major continuing glucose monitoring customers that had begun transitioning to in-house manufacturing of next-generation devices after West 'made the decision to not participate going forward as our financial thresholds cannot be achieved.' West also revealed that its SmartDose wearable injector devices would be 'margin-dilutive' in 2025 and that it would be 'taking steps to improve [its SmartDose] economics, and all options are on the table.'
On this news, West's stock dropped $123.17 per share, a decline of 38 percent, to close at $199.11 on February 13, 2025.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding West's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the West Pharmaceutical Services class action, go to www.faruqilaw.com/WST or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
2 Dirt Cheap Stocks to Buy With $200 Right Now
Shares of Carnival are rising as the cruise line pays off its debt, but the stock still remains very cheap. Williams-Sonoma shares are starting to climb as it demonstrates resilience in a tough environment. 10 stocks we like better than Carnival Corp. › With the S&P 500 index up 6% this year and hitting new highs, we're back to a thriving bull market. Investors love to see their stocks fly, but the flip side of that is that it's harder to find great deals. Consider that the average S&P 500 P/E ratio continues to balloon as the market rises. If you're worried about finding good deals in the market, that's a valid concern. But it doesn't mean they don't exist. Consider Carnival (NYSE: CCL) (NYSE: CUK) and Williams-Sonoma (NYSE: WSM), which are trading at dirt cheap prices despite running excellent businesses and having a long growth runway. Carnival is the leading global cruise operator, a one-time market beater that's fallen due to extreme debt. Its business is back to flourishing after a short pause early in the pandemic, but while it continues to break its own record quarter after quarter across metrics, Carnival stock is still 60% off its highs. As it keeps reporting near-flawless performance and paying off its debt, the stock price is rising -- up 64% over the past year. Yet, it trades at a price-to-sales ratio of 1.5 and a forward, one-year P/E ratio under 13, and it's not too late to buy. In its fiscal 2025's second quarter (ended May 31), it beat internal guidance as well as Wall Street expectations to post new records. Revenue increased about 9% year over year to $6.3 billion, and operating income was up from $560 million last year to $934 million this year. Earnings per share increased from $0.07 last year to $0.42 this year. Carnival had record deposits of $8.5 billion, and it's maintaining its historically high bookings at high ticket prices; plus, it's booked out for an increasingly long curve. There have been worries that demand will dry up before the company can get back to a reasonable debt level, but so far demand is remaining strong even as Carnival efficiently pays off its debt. The cruise line ended the quarter with $27 billion in total debt, and it has refinanced $7 billion so far this year at more favorable rates. It has had two upgrades from credit ratings agencies that bring it one notch away from investment grade. Carnival stock may not be the right choice for the most risk-averse investor, but if you can handle some risk, Carnival should bounce back and reward shareholders. Williams-Sonoma owns several brands that target the upscale housewares shopper. Although its customer is generally more resilient than the mass consumer, it has struggled along with its industry as macroeconomic pressure persists. The real estate industry is still sluggish, and that has impacted all kinds of home improvement. However, the situation is improving, and the company reported solid results for its most recent period, the fiscal 2025 first quarter (ended May 4). Comparable brand revenue, its preferred top-line metric, increased 3.4% year over year, and operating margin was 16.8%, exceeding guidance. The retailer is well fortified to handle changes in tariffs since it has a diversified supplier base, with only 23% coming from China, and it reiterated its full-year outlook after the first quarter. Current performance demonstrates the company's strength under pressure, which should boost investor confidence. But it's the long-term outlook that makes the stock look like a buy for the future. One of what it calls its key differentiators is "digital first, not digital only," and that's the way most retailers are succeeding today. Having been at it a long time, Williams-Sonoma has a robust omnichannel strategy, and e-commerce now accounts for a majority of total sales -- 66% in the 2025 fiscal first quarter. It sees a $830 billion addressable market, especially as the industry moves online, where it already has an edge. Williams-Sonoma stock is down 8% this year, but it's already climbing back up on investor enthusiasm. Plus, it pays a dividend that yields 1.4% right now. At the current price, it trades at a forward, one-year P/E ratio of 19, and this could be a great entry point for investors on the fence. Before you buy stock in Carnival Corp., consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Carnival Corp. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Jennifer Saibil has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Williams-Sonoma. The Motley Fool recommends Carnival Corp. The Motley Fool has a disclosure policy. 2 Dirt Cheap Stocks to Buy With $200 Right Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Is Annaly Capital Stock a Millionaire Maker?
Annaly Capital increased its dividend at the start of 2025. The mortgage REIT has a huge 14%+ dividend yield. Make sure you understand what you are buying before you chase Annaly's lofty yield. 10 stocks we like better than Annaly Capital Management › Annaly Capital Management (NYSE: NLY) has an enticing 14%+ dividend yield backed by a dividend that was just increased. Some on Wall Street believe that the safest dividends are those that have just been raised. But don't let greed drive your decision-making; there's more to know about Annaly than just the size of its dividend yield if you want to become a millionaire someday. Annaly Capital is a real estate investment trust (REIT). However, unlike most REITs, it doesn't purchase properties. Traditional REITs essentially do what you would do if you owned a rental property, but they do it on an institutional scale. Annaly buys mortgages that have been pooled into bond-like securities. This is a vastly different business model, one that would be very hard for a small investor to replicate in any way. Essentially, Annaly aims to earn the difference between the interest it earns from the mortgage securities it buys and its costs. Those costs include general operating expenses, as well as the cost of leverage. A significant portion of the leverage Annaly uses amounts to loans backed by the mortgage securities it owns. This is not a low-risk business. Moreover, unlike a physical property, mortgage securities trade all day long, leading to swift changes in the value of the portfolio. Factors such as interest rates, housing market dynamics, and even mortgage repayment rates can impact mortgage security prices. It would be hard for most investors even to track what's going on here. Basically, mortgage REITs (mREITs) like Annaly should probably be owned only by more active and perhaps more aggressive investors -- notice that statement didn't include dividend investors. If you are trying to build wealth with dividend stocks, Annaly won't be a good fit for your portfolio. The chart above shows you all you need to know. The orange line is the annual dividend, which has been highly volatile. And up until the recent increase, it had been heading lower for years. The purple line is the stock price, which has been just as volatile as the dividend, and it, too, has been trending lower for years. A lofty dividend yield hasn't translated into a reliable and perhaps growing income stream, which is what most long-term dividend investors are really looking for. But there's an important nuance here, as Annaly Capital isn't actually focused on the dividend per se; it's focused on generating total return. That assumes that dividends get reinvested, not spent on daily living expenses. If you are focused on total return, Annaly has been a win. Notice in the chart above that its total return has kept pace with that of the S&P 500 (SNPINDEX: ^GSPC) over time. But the two don't move in lockstep, which makes Annaly an interesting candidate for adding to an asset allocation model, as it offers attractive diversification potential. While dividend investors may not find Annaly to their liking, asset allocators may like it a great deal. Annaly Capital's ability to help you reach millionaire status depends greatly on what you are trying to achieve when you buy a stock. If the goal is to generate a reliable and growing income stream, even if you aren't yet using that income, history suggests that Annaly will likely be a big letdown. It just isn't focused on that goal. However, if you are laser-focused on total return and like to have a portfolio diversified across different asset classes, this mREIT could be right up your alley. Just go in knowing that dividend reinvestment is what lets Annaly meet its total return goal. Before you buy stock in Annaly Capital Management, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Annaly Capital Management wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Is Annaly Capital Stock a Millionaire Maker? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
UnitedHealth Group Incorporated (UNH): 'Medicare Fraud Is Prison,' Warns Jim Cramer
We recently published . UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer recently discussed. UnitedHealth Group Incorporated (NYSE:UNH) is the largest healthcare benefits provider in America. It is also one of the worst-performing stocks in 2025 as the shares have lost 40% year-to-date. UnitedHealth Group Incorporated (NYSE:UNH)'s shares sank by a massive 27.3% in April after the firm stunned investors by missing analyst estimates for its latest quarter. Cramer's recent remarks about the firm discussed media reports of impropriety and pointed out that UnitedHealth Group Incorporated (NYSE:UNH) wouldn't be buying shares if they were true. However, this time, he had a much darker tone: '[On a WSJ report that UNH deploys doctors and nurses to gather diagnoses that bolster its payments with UNH responding that it welcomes reviews] Well I'm glad they welcome it but I do want to caution them, and I think I happen to like this CEO very much, but Medicare fraud is prison. It's not, hey listen we'll slap UNH on the wrist. It's prison. And it's probably the most I think easily, the crimes are easily followed and the judgement is swift. The reason why people are so focused on this is that it's not a fine.' Previously, the CNBC host discussed UnitedHealth Group Incorporated (NYSE:UNH) in detail: 'The third worst performer was, wow, UnitedHealth Group, suddenly very troubled managed care company that used to be the ultimate darling in the group. It's down 38% in the first half. UnitedHealth's troubles are very well documented. I'm not even talking about the assassination last December, as terrible as that was. The real trouble started in April when the company reported a weak quarter, dragged down by high utilization rates, meaning people are getting much more healthcare than UNH… needs to pay for. A senior healthcare professional giving advice to a patient in a clinic. What's starting to become clear is that the company made some major missteps with its underwriting, especially with Medicare Advantage plans for seniors. They're far from the only one in the industry with this problem, but UNH might be the hardest hit. This is the largest player in the Medicare Advantage space with the most extensive data, and they really should have been able to avoid these mistakes. They almost always have, but clearly, they didn't. The company made a change in the top mid-May with CEO Andrew Witty stepping down for personal reasons. Turning around UNH is now the job of Stephen Hemsley, whom I really like. He was previously CEO from 2006 to 2017. And there's some nascent optimism that he can get this business back on track, but I don't necessarily think this will happen quickly. If you're inclined to bet on a UNH comeback, I suggest that you take it slowly because you got all the time in the world. You actually might even want to wait to see the next quarter, which could be what we call a clearing event for the negatives.' While we acknowledge the potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
